-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, GKNmD9DirzSCdigpIN3X/378hUexm3Twc3Kp53WOgqXDCxYAauLeHgH35Dwf0uBF KPD+oKfYsGEcpza+mhlo/w== 0001209191-09-051130.txt : 20091104 0001209191-09-051130.hdr.sgml : 20091104 20091104213922 ACCESSION NUMBER: 0001209191-09-051130 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20091103 FILED AS OF DATE: 20091104 DATE AS OF CHANGE: 20091104 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: KELLOGG PETER N CENTRAL INDEX KEY: 0001226287 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-03305 FILM NUMBER: 091159278 MAIL ADDRESS: STREET 1: BIOGEN INC LEGAL DEPARTMENT STREET 2: 14 CAMBRIDGE CENTER CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: MERCK SHARP & DOHME CORP. CENTRAL INDEX KEY: 0000064978 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 221109110 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE MERCK DR STREET 2: P O BOX 100 CITY: WHITEHOUSE STATION STATE: NJ ZIP: 08889-0100 BUSINESS PHONE: 9084231688 MAIL ADDRESS: STREET 1: ONE MERCK DR STREET 2: PO BOX 100 WS3AB-05 CITY: WHITEHOUSE STATION STATE: NJ ZIP: 08889-0100 FORMER COMPANY: FORMER CONFORMED NAME: MERCK & CO INC DATE OF NAME CHANGE: 19920703 4 1 c91981_4x0.xml MAIN DOCUMENT DESCRIPTION X0303 4 2009-11-03 1 0000064978 MERCK SHARP & DOHME CORP. MRK 0001226287 KELLOGG PETER N ONE MERCK DRIVE WHITEHOUSE STATION NJ 08889-0100 0 1 0 0 Exec. V.P. & C.F.O Restricted Stock Unit 2009-11-03 4 D 0 80000.0000 0 D 2010-11-13 2013-11-13 Common Stock 80000.0000 0.0000 D Restricted Stock Unit 2009-11-03 4 D 0 11700.0000 0 D 2011-02-28 2011-02-28 Common Stock 11700.0000 0.0000 D Restricted Stock Unit 2009-11-03 4 D 0 17550.0000 0 D 2012-04-24 2012-04-24 Common Stock 17550.0000 0.0000 D Stock Option (right to buy) 57.4900 2009-11-03 4 D 0 175000.0000 0 D 2008-11-13 2017-11-12 Common Stock 175000.0000 0.0000 D Stock Option (right to buy) 44.3000 2009-11-03 4 D 0 62400.0000 0 D 2009-02-28 2018-02-28 Common Stock 62400.0000 0.0000 D Stock Option (right to buy) 23.4500 2009-11-03 4 D 0 93600.0000 0 D 2010-04-24 2019-04-23 Common Stock 93600.0000 0.0000 D Each restricted stock unit represents a contingent right to receive one share of Old Merck common stock and was (i) assumed by the Surviving Corporation in the Transactions and (ii) converted into a restricted stock unit representing a contingent right to receive one share of Surviving Corporation Common Stock on the same vesting schedule as applied prior to the Transactions. 40,000 restricted stock units will vest on November 13, 2010 and 40,000 restricted stock units will vest on November 13, 2013. Each restricted stock unit represents a contingent right to receive one share of Old Merck common stock and was (i) assumed by the Surviving Corporation in the Transactions and (ii) converted into a restricted stock unit representing a contingent right to receive one share of Surviving Corporation Common Stock on the same vesting schedule as applied prior to the Transactions. This option to purchase shares of Old Merck common stock, which vesting in five equal annual installments beginning November 13, 2008, was assumed by the Surviving Corporation in the Transactions and continued on the same terms and conditions as an option to purchase an equivalent number of shares of Surviving Corporation Common Stock at the same exercise price as applied prior to the Transactions. This option to purchase shares of Old Merck common stock, which vesting in three equal annual installments beginning on year from date of grant, was assumed by the Surviving Corporation in the Transactions and continued on the same terms and conditions as an option to purchase an equivalent number of shares of Surviving Corporation Common Stock at the same exercise price as applied prior to the Transactions. /s/ Debra A. Bollwage as Attorney-in-Fact for Peter N. Kellogg 2009-04-11 -----END PRIVACY-ENHANCED MESSAGE-----